Detalhe da pesquisa
1.
PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2.
Kidney Int
; 103(1): 207-217, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36007597
2.
Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria.
Kidney Int
; 101(3): 626-634, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34481803
3.
Safety, Pharmacokinetics, and Exposure-Response Modeling of Nedosiran in Participants With Severe Chronic Kidney Disease.
Clin Pharmacol Drug Dev
; 12(12): 1164-1177, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37605486
4.
Quantification of antibody-drug conjugate PYX-201 in rat and monkey plasma via ELISA and its application in preclinical studies.
Bioanalysis
; 15(1): 43-52, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36876967
5.
A sensitive LC-MS/MS assay to quantitate free payload Aur0101 from ADC PYX-201 in rat and monkey plasma.
Bioanalysis
; 15(14): 833-843, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37584364
6.
Quantitation of total antibody (tAb) from antibody drug conjugate (ADC) PYX-201 in rat and monkey plasma using an enzyme-linked immunosorbent assay (ELISA) and its application in preclinical studies.
J Pharm Biomed Anal
; 233: 115452, 2023 Sep 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37167766
7.
Celecoxib inhibits proliferation of retinal pigment epithelial and choroid-retinal endothelial cells by a cyclooxygenase-2-independent mechanism.
J Pharmacol Exp Ther
; 324(2): 749-58, 2008 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-18032574
8.
Modeling of corneal and retinal pharmacokinetics after periocular drug administration.
Invest Ophthalmol Vis Sci
; 49(1): 320-32, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18172109
9.
Effect of eye pigmentation on transscleral drug delivery.
Invest Ophthalmol Vis Sci
; 49(1): 333-41, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18172110
10.
Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration.
Mol Vis
; 14: 150-60, 2008 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-18334929
11.
Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage.
Invest Ophthalmol Vis Sci
; 47(3): 1149-60, 2006 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-16505053
12.
Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration.
J Pharm Pharmacol
; 57(12): 1555-63, 2005 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-16354399
13.
Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas.
Eur J Pharmacol
; 498(1-3): 275-8, 2004 Sep 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-15364005
14.
Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.
Prog Retin Eye Res
; 36: 172-98, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23603534
15.
Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes.
Expert Opin Drug Deliv
; 7(5): 631-45, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20205602
16.
In vitro transport and partitioning of AL-4940, active metabolite of angiostatic agent anecortave acetate, in ocular tissues of the posterior segment.
J Ocul Pharmacol Ther
; 26(2): 137-46, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20415622
17.
Effect of diabetes on transscleral delivery of celecoxib.
Pharm Res
; 26(2): 404-14, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-18987961